Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-1.02
EPS est.
$-0.92
EPS surprise
-10.87%
1-day move
+0.04%
Arcus Biosciences reported a wider loss per share than analysts expected, which typically raises concerns about profitability. However, the stock saw a slight increase of 0.04%, indicating that investors may have had lower expectations going into the report. The lack of revenue data and management commentary leaves uncertainty about the company's performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.02 | $-0.83 | -10.87% |
| Revenue | — | $29M | — |
No transcript is on record, and the analysis is based on numerical results only.
Arcus Biosciences, Inc. is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, it aims to address significant unmet medical needs in oncology, which is crucial as cancer remains one of the leading causes of death worldwide.
Last quarter
In the last quarter, Arcus reported an EPS of $-0.89, which was better than analysts' expectations of $-1.11, resulting in a positive stock reaction of 0.40%. However, revenue details were not disclosed, leaving some uncertainty about overall performance.
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+18.34%
Avg 1-day reaction
-0.33%
Analysts expect a loss of $0.83 per share and revenue of $29 million for Q1-2026. The market is watching closely for any signs of improved financial performance or updates on drug development.
Bull case
If Arcus can beat the EPS estimate and show strong revenue growth, it may indicate successful advancements in its drug pipeline, potentially boosting investor confidence.
Bear case
Conversely, if the company reports a larger loss than expected or disappointing revenue, it could raise concerns about its financial stability and future growth prospects.
Key metrics to watch
EPS
$-0.83Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$29MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the company achieve an EPS better than the consensus estimate of $-0.83?
A beat on EPS could signal improved operational efficiency and investor confidence in the company's future.
Q2
What are the revenue figures compared to the expected $29 million?
Revenue performance is critical to understanding market demand and the potential success of its product pipeline.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may be overly pessimistic about revenue growth, as Arcus has a strong pipeline that could yield better-than-expected results.
Supporting evidence
The company has a history of beating EPS estimates, with an 88% beat rate over the last eight quarters.
The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.
Key risk
If the revenue comes in above $40 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized as investors seek clarity on the company's growth trajectory and financial health.
Bull confirmed if
An EPS of $-0.65 or better, along with revenue exceeding $40 million, would confirm the bull case.
Bear confirmed if
An EPS worse than $-1.01 and revenue below $7 million would confirm the bear case.
What the market is pricing for the move.
Implied Move
±30.18%
Historical Avg
±3.1%
The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±22.3% while RCUS has averaged ±3.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
61.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
74.92%
of float
Insider
28.80%
of float
Holders
329
institutions
Top Holders· as of Jun 2026
Gilead Sciences Inc
31,424,760 sh · $770.5M
24.68%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Arcus beats expectations, history suggests a positive stock reaction of around +0.88%, confirming a bullish outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction, reflecting cautious investor sentiment.
Miss
A miss could lead to a significant drop, with historical data indicating an average decline of -9.17% following earnings misses.
The lines on the call that would change the story.
Blackrock Inc.
16,416,249 sh · $402.5M
12.89%
7.8%
State Street Corporation
6,029,484 sh · $147.8M
4.74%
11.4%
Wellington Management Group, LLP
5,895,448 sh · $144.6M
4.63%
-3.2%
Montanova Capital LLC
4,776,423 sh · $117.1M
3.75%
-5.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.